



Adopted as Rule: September 30, 2013

Toxicological Summary for 1,4-Dioxane:

CAS: 123-91-1

Synonyms: diethylene ether; 1,4-diethylene dioxide; diethylene oxide; dioxyethylene ether; and dioxane

Acute Non-Cancer Health Risk Limit (nHRL_{acute}) = Not Derived (Insufficient Data)

Short-term Non-Cancer Health Risk Limit (nHRL_{short-term}) = Not Derived (Insufficient Data)

Subchronic Non-Cancer Health Risk Limit (nHRL_{subchronic}) = 300 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Subchronic intake rate, L/kg/d})}$$

$$= \frac{(0.12 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.077 \text{ L/kg-d})}$$

$$= 312 \text{ rounded to } \mathbf{300 \text{ µg/L}}$$

Reference Dose / Concentration: 0.12 mg/kg-d (F344/DuCrj rats)
Source of toxicity value: MDH 2011
Point of Departure: 52 mg/kg-d (NOAEL from 13 week drinking water study in rats by Kano et al 2008)
Human Equivalent Dose Adjustment: 52 mg/kg-d x DAF = 52 x 0.23 = 12 mg/kg-d (MDH 2011)
Total uncertainty factor: 100
UF allocation: 3 for interspecies extrapolation to address potential differences in toxicodynamics (toxicokinetic differences are address by the HED adjustment); 10 for intraspecies variability; and 3 for database insufficiencies (lack of a multigeneration reproductive/developmental study)
Critical effect(s): Increased relative liver and kidney weight (with histological and clinical chemistry changes at higher dose level); hepatocyte swelling; and nuclear enlargement of the nasal respiratory epithelium
Co-critical effect(s): Increased nuclear enlargement of the bronchial epithelium
Additivity endpoint(s): Hepatic (liver) system, Renal (kidney) system, Respiratory system

Chronic Non-Cancer Health Risk Limit (nHRL_{chronic}) = 100 µg/L

$$= \frac{(\text{Reference Dose, mg/kg-d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Chronic intake rate, L/kg-d})}$$

$$= \frac{(0.025 \text{ mg/kg-d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.043 \text{ L/kg-d})}$$

$$= 116 \text{ rounded to } \mathbf{100 \text{ µg/L}}$$

Reference Dose / Concentration: 0.025 mg/kg-d (Sherman rats)

Source of toxicity value: MDH 2011 (Note: same basis as EPA IRIS 2010 value that was rounded to 0.03 mg/kg-d)

Point of Departure: 9.6 mg/kg-d (NOAEL from 2 year drinking water study in rats by Kociba et al 1974)

Human Equivalent Dose Adjustment: 9.6 mg/kg-d x DAF = 9.6 x 0.26 = 2.5 mg/kg-d (EPA IRIS 2010, Table 5-7)

Total uncertainty factor: 100

UF allocation: 3 for interspecies extrapolation to address potential differences in toxicodynamics (toxicokinetic differences are addressed by the HED adjustment); 10 for intraspecies variability; and 3 for database insufficiencies (lack of a multigeneration reproductive/developmental study)

Critical effect(s): Histopathological lesions in the liver and kidney (hepatic and renal degeneration and necrosis as well as regenerative hyperplasia in hepatocytes and renal tubule epithelial cells)

Co-critical effect(s): Increased relative liver weight; nonneoplastic lesions in the nasal cavity, liver and kidney; nuclear enlargement of nasal, tracheal and bronchial epithelium; decreased body weight and growth; and neoplastic lesions in the liver**

Additivity endpoint(s): Hepatic (liver) system; Renal (kidney) system; Respiratory system

**neoplastic lesions (liver adenomas) are addressed by the Cancer HRL

Cancer Health Risk Limit (cHRL) = 1 µg/L

$$= \frac{(\text{Additional Lifetime Cancer Risk}) \times (\text{Conversion Factor})}{[(\text{SF} \times \text{ADAF}_{<2 \text{ yr}} \times \text{IR}_{<2 \text{ yr}} \times 2) + (\text{SF} \times \text{ADAF}_{2-16 \text{ yr}} \times \text{IR}_{2-16 \text{ yr}} \times 14) + (\text{SF} \times \text{ADAF}_{16+ \text{ yr}} \times \text{IR}_{16+ \text{ yr}} \times 54)] / 70}$$

$$= \frac{(1\text{E-}5) \times (1000 \text{ µg/mg})}{[(0.10 \times 10 \times 0.137 \text{ L/kg-d} \times 2) + (0.10 \times 3 \times 0.047 \text{ L/kg-d} \times 14) + (0.10 \times 1 \times 0.039 \text{ L/kg-d} \times 54)] / 70}$$

$$= 1.03 \text{ rounded to } \mathbf{1 \text{ µg/L}}$$

Cancer classification: "Likely to be carcinogenic to humans"

Slope factor: 0.10 per mg/kg-d (laboratory animal) (hepatocellular adenomas and carcinomas in female mice, Kano et al 2009)

Source of slope factor: US EPA, IRIS 2010 (United States Environmental Protection Agency 2010)

Tumor site(s): Slope factor based on liver adenomas and carcinomas. Additional

tumor sites included: nasal squamous cell carcinomas; peritoneal mesotheliomas; and mammary gland adenomas

Volatile: Yes (low volatile)

Summary of Guidance Value History:

In 2002, MDH derived a cancer Health-Based Value (HBV) of 30 µg/L. In 2011, the cancer HBV was updated to 1 µg/L. The 2011 cancer HBV was 30-fold lower as the result of: 1) use of a more recent cancer risk assessment; 2) application of age-dependent early-life cancer sensitivity adjustment factors; 3) utilizing more recent intake rates which incorporate higher intake rates during early life, and 4) rounding to one significant figure. The noncancer subchronic and chronic HBVs were new in 2011. The 2011 HBVs were adopted as HRLs in 2013.

Summary of toxicity testing for health effects identified in the Health Standards Statute:

	Endocrine	Immunotoxicity	Development	Reproductive	Neurotoxicity
Tested?	No ¹	No ²	Yes	No ⁴	Yes
Effects?	-	-	Yes ³	-	Yes ⁵

Note: Even if testing for a specific health effect was not conducted for this chemical, information about that effect might be available from studies conducted for other purposes. Most chemicals have been subject to multiple studies in which researchers identify a dose where no effects were observed, and the lowest dose that caused one or more effects. A toxicity value based on the effect observed at the lowest dose across all available studies is considered protective of all other effects that occur at higher doses.

Comments on extent of testing or effects:

¹⁾ Relevant oral toxicity studies have not been conducted. However, based on available indirect information there is no evidence that 1,4-dioxane exhibits endocrine activity.

²⁾ No oral immunotoxicity studies. Based on available indirect information there is no evidence that 1,4-dioxane alters immune function.

³⁾ Only one oral study, a teratogenicity study in rats (Giavini et al 1985) is available. In this study, pregnant females and their fetuses exposed to a human equivalent dose of 230 mg/kg-d ($\geq$ 2000-fold higher than the subchronic and chronic RfDs) weighed less than unexposed animals. A slightly but significantly higher incidence of reduced sternum ossification was also noticed in these exposed fetuses. No other significant differences between treated and control groups were observed, including number of implantations and of live fetuses, post-implantation loss, and incidence of malformations.

⁴⁾ No oral reproductive studies have been conducted and therefore only ancillary information is available.

⁵⁾ In laboratory animals, the neurological effects of acute high-dose exposure included staggered gait, narcosis, paralysis, coma, and death. A single oral dose at a human equivalent dose level of 252 mg/kg-d ($\geq$ 2000-fold higher than the subchronic and chronic RfDs) resulted in reduced the dopamine and serotonin content of the hypothalamus, the neurochemical profile of all other brain regions were not affected.

No repeat oral dosing studies evaluating neurotoxicity per se have been conducted and therefore only ancillary information is available. No histopathologic alterations were observed in the brain, spinal cord,

and sciatic nerve from rats receiving up to 2 year exposure via the drinking water at dose levels up to ~1600 mg/kg-d [HED ~ 416] (~3500-fold higher than the subchronic and chronic RfDs).

References:

- Agency for Toxic Substances and Disease Registry (ATSDR) - MRLs. (2009). "Minimal Risk Levels for Hazardous Substances (MRLs)." from http://www.atsdr.cdc.gov/mrls/mrls_list.html.
- Agency for Toxic Substances and Disease Registry (ATSDR) - Toxicological Profiles. "Toxicological Profile Information Sheet." from <http://www.atsdr.cdc.gov/toxpro2.html>.
- Agency for Toxic Substances and Disease Registry (ATSDR) (2007). Draft Toxicological Profile for 1,4-Dioxane.
- Australian Guidelines- Natural Resource Management Ministerial Council; Environmental Protection and Heritage Council; and National Health and Medical Research Council. (2008). "Augmentation of Drinking Water Supplies." from http://www.ephc.gov.au/sites/default/files/WQ_AGWR_GL_ADWS_Corrected_Final_%20200809.pdf.
- California Environmental Protection Agency-OEHHA Toxicity Criteria Database. from <http://www.oehha.ca.gov/risk/ChemicalDB/index.asp>.
- California Environmental Protection Agency - OEHHA Proposition 65. "Most Current Proposition 65 No Significant Risk Levels (NSRLs) Maximum Allowable Dose Levels (MADLs)." from <http://www.oehha.ca.gov/prop65/getNSRLs.html>.
- California State Water Resources Control Board (2010). Monitoring Strategies for Chemicals of Emerging Concern (CECs) in Recycled Water. Recommendations of a Science Advisory Panel.
- California Water Resources Control Board. (2008). "Water Quality Limits for Constituents and Parameters." from http://www.waterboards.ca.gov/water_issues/programs/water_quality_goals/docs/limit_tables_2008.pdf.
- Environment Canada and Health Canada (March 2010). Screening Assessment for the Challenge: 1,4-Dioxane (Chemical Abstracts Service Registry Number 123-91-1).
- European Chemicals Bureau (2002). European Union Risk Assessment Report: 1,4-Dioxane.
- European Commission Scientific Committee on Food (2002). Opinion of the Scientific Committee on Food on Impurities of 1,4-dioxane, 2-chloroethanol and mono- and diethylene glycol in currently permitted food additives and in proposed use of ethyl hydroxyethyl cellulose in gluten-free bread.
- European Union Pesticide Database. from http://ec.europa.eu/sanco_pesticides/public/index.cfm.
- Giavini E, C. V., ML Broccia, (1985). "Teratogenesis study of dioxane in rats." Toxicology Letters **26**: 85-88.
- Health Canada - Guidelines for Canadian Drinking Water Quality.

- Health Canada - Priority Substances Assessment Program and Screening Assessment Reports. from <http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/index-eng.php#existsub>.
- HERA - Human Environmental Risk Assessment on Ingredients of household cleaning products. from <http://www.heraproject.com/RiskAssessment.cfm>.
- International Agency for Research on Cancer (IARC). "Complete List of Agents evaluated and their classification." from <http://monographs.iarc.fr/ENG/Classification/index.php>.
- International Agency for Research on Cancer (IARC) (1987). 1,4-Dioxane
- Kano H, Y. U., M Saito, H Senoh, H Ohbayashi, S Aiso, K Yamazaki, K Nagano, S Fukushima, (2008). "Thirteen-week oral toxicity of 1,4-dioxane in rats and mice." The Journal of Toxicological Sciences **33**(2): 141-153.
- Kano H, Y. U., T Kasai, T Sasaki, M Matsumoto, K Yamazaki, K Nagano, H Arito, S Fukushima, (2009). "Carcinogenicity studies of 1,4-dioxane administered in drinking water to rats and mice for 2 years." Food and Chemical Toxicology **47**(11): 2776-2784.
- Kociba RJ, S. M., C Park, TR Torkelson, PJ Gehring, (1974). "1,4-Dioxane. I. Results of a 2-Year Ingestion Study in Rats." Toxicology and Applied Pharmacology **30**: 275-286.
- Minnesota Department of Health (MDH). (2011). "MDH Health Risk Assessment Methods to Incorporate Human Equivalent Dose Calculations into Derivation of Oral Reference Doses." from <http://www.health.state.mn.us/divs/eh/risk/guidance/hedrefguide.pdf>.
- National Cancer Institute (1978). Technical Report Series NO. 80: Bioassay of 1,4-Dioxane for Possible Carcinogenicity.
- National Industrial Chemicals Notification and Assessment Scheme (NICNAS), C. o. A. (1998). 1,4-Dioxane: Priority Existing Chemical No. 7.
- National Toxicology Program. from <http://ntp.niehs.nih.gov/?objectid=25BC6AF8-BDB7-CEBA-F18554656CC4FCD9>.
- Schriks M, M. H., MME van der Kooi, P de Voogt, AP van Wezel, (2010). "Toxicological relevance of emerging contaminants for drinking water quality." Water Research **44**: 461-476.
- Syracuse Research PhysProp Database. from <http://www.syrres.com/what-we-do/databaseforms.aspx?id=386>.
- The International Programme on Chemical Safety. "Chemicals Assessment." from <http://www.who.int/ipcs/assessment/en/>.
- Toxicology Excellence for Risk Assessment - ITER "International Toxicity Estimates for Risk (ITER)." from http://iter.ctcnet.net/publicurl/pub_search_list.cfm.
- TOXNET. "Toxicology Data Network Search." from <http://toxnet.nlm.nih.gov/>.
- U. S. Environmental Protection Agency - IRIS. "Integrated Risk Information Systems (IRIS) A-Z List of Substances." from <http://cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList>.

- U. S. Environmental Protection Agency - National Center for Environmental Assessment. from http://cfpub.epa.gov/ncea/cfm/archive_whatsnew.cfm.
- U. S. Environmental Protection Agency - Office of Drinking Water. "2006 Edition of the Drinking Water Standards and Health Advisories." from <http://www.epa.gov/waterscience/criteria/drinking/dwstandards.pdf>.
- U. S. Environmental Protection Agency - Office of Pesticide Programs Reregistration Status. "Pesticide Registration Status." from <http://www.epa.gov/pesticides/reregistration/status.htm>.
- U. S. Environmental Protection Agency - Voluntary Children's Chemical Evaluation Program (VCCEP). "VCCEP Chemicals." from <http://www.epa.gov/oppt/vccep/pubs/chemmain.html>.
- U. S. Environmental Protection Agency -Toxicity and Exposure Assessment for Children's Health (TEACH). from <http://www.epa.gov/teach/>.
- U. S. Geological Survey - Health-Based Screening Levels. from <http://infotrek.er.usgs.gov/apex/f?p=HBSL:HOME:0>.
- U.S. Environmental Protection Agency - Office of Research and Development. (1988). "Recommendations for and Documentation of Biological Values for Use in Risk Assessment." from <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855>.
- U.S. Environmental Protection Agency - Office of the Science Advisor. (2011). "Recommended Use of Body Weight^{3/4} as the Default Method in Derivation of the Oral Reference Dose." from <http://www.epa.gov/raf/publications/pdfs/recommended-use-of-bw34.pdf>.
- U.S. Environmental Protection Agency - Provisional Peer Reviewed Toxicity Values for Superfund (PPRTV). from http://hhpprtv.ornl.gov/quickview/pprtv_papers.php.
- U.S. Environmental Protection Agency - Regional Screening Tables. "Mid-Atlantic Risk Assessment - Regional Screening Table." from http://www.epa.gov/reg3hwmd/risk/human/rb-concentration_table/index.htm.
- United States Environmental Protection Agency (2010). Toxicological Review of 1,4-Dioxane (CAS No. 123-91-1).
- Wisconsin Department of Health Services (2009). Scientific Support Documentation for Cycle 9. Revisions of NR 140.10 Groundwater Enforcement Standard & Preventative Action Limit Recommendations.
- World Health Organization - Guidelines for Drinking-Water Quality. (2008). from http://www.who.int/water_sanitation_health/dwq/gdwq3rev/en/index.html.